Yes — in type 2 diabetes GLP-1 receptor agonists improve kidney outcomes, but only FLOW proves a hard renal endpoint; earlier trials' benefit is largely albuminuria-driven.
Summary
In type 2 diabetes and CKD, once-weekly semaglutide (FLOW) is the single trial prospectively powered on a kidney composite and shows a significant reduction extending beyond albuminuria [1,2]. Earlier cardiovascular outcome trials — LEADER (liraglutide) and REWIND (dulaglutide) — reported favourable renal composites, but those composites were driven overwhelmingly by new-onset macroalbuminuria rather than eGFR loss or kidney failure [3,4,5]. The honest reading is that the class robustly lowers albuminuria across agents, whereas confirmed benefit on hard renal endpoints rests essentially on FLOW; there is no comparable hard-endpoint evidence in non-diabetic CKD, and several claims here rest on abstracts rather than full text.
Key findings
- FLOW is the only GLP-1 RA trial designed with a kidney composite as its primary endpoint in type 2 diabetes and CKD, and its primary results report a significant reduction versus placebo with benefit extending beyond albuminuria [1,2].
- LEADER (liraglutide) reported a lower rate of its renal composite, but that composite was dominated by new-onset persistent macroalbuminuria; the hard components (sustained eGFR decline, ESKD, renal death) did not independently drive the result [3].
- REWIND (dulaglutide) showed a reduced renal composite in an exploratory analysis, again largely attributable to new macroalbuminuria; post hoc kidney-function analyses show a more modest eGFR-based signal [4,6].
- Surrogate-endpoint evidence is consistent and cross-agent: AWARD-7 (dulaglutide) and pooled SURPASS-1–5 (tirzepatide, a dual GIP/GLP-1 agonist) both show albuminuria reduction — reinforcing an albuminuria class effect distinct from proven hard-endpoint protection [7,8].
- Meta-analyses of cardiovascular outcome trials estimate a favourable pooled kidney composite (~HR 0.83), but this is inflated by albuminuria components and should not be read as pooled protection against kidney failure [5,9].
- FLOW pre-specified analysis indicates the kidney benefit of semaglutide is present with and without concomitant SGLT2 inhibitor use, supporting a degree of additive/independent effect [10].
Evidence
| Evidence | Detail | Sources |
|---|---|---|
| Dedicated hard-endpoint trial (FLOW, semaglutide) | FLOW enrolled type 2 diabetes patients with CKD and used a kidney composite as its primary endpoint. The primary-results abstract reports a significant reduction versus placebo with benefit extending beyond albuminuria; the design/baseline paper confirms it as a dedicated kidney-outcomes trial. Full text was not available this session, so effect detail is at abstract level. | [1], [2] |
| CVOTs with renal composites driven by albuminuria (LEADER, REWIND) | LEADER and REWIND both reported reduced renal composites, but in each the effect was dominated by new-onset macroalbuminuria rather than sustained eGFR decline, ESKD, or renal death. These trials were not powered for hard renal endpoints. REWIND post hoc kidney-function analysis shows a weaker signal on eGFR-based outcomes. | [3], [4], [6] |
| Albuminuria surrogate signal across agents (AWARD-7, SURPASS pooled) | AWARD-7 showed dulaglutide effects by albuminuria status versus insulin glargine in diabetes and CKD; a pooled post hoc of SURPASS-1–5 showed tirzepatide reduced albuminuria. Together these support a consistent cross-agent albuminuria-lowering effect, which is a surrogate and not equivalent to hard-endpoint protection. | [7], [8] |
| Meta-analytic pooling and SGLT2i interaction | Meta-analyses of CVOTs estimate a favourable pooled kidney composite (~HR 0.83), but the composite includes albuminuria, so it overstates hard-endpoint benefit. FLOW analysis suggests semaglutide's kidney benefit holds with and without concomitant SGLT2 inhibitors. | [5], [9], [10] |
Figures
Kidney outcomes by GLP-1 RA trial: endpoint tested and effect direction
FLOW (semaglutide) — hard kidney composite
LEADER (liraglutide) — kidney composite (albuminuria-driven)
REWIND (dulaglutide) — kidney composite (albuminuria-driven)
Meta-analysis (Kristensen) — broad kidney composite
From session data HR point estimates taken from the cited trial/meta-analysis abstracts (FLOW, LEADER, REWIND, Kristensen meta-analysis). (FLOW primary results (PMID 38785209), LEADER renal outcomes (PMID 28854085), REWIND renal exploratory (PMID 31189509), Kristensen meta-analysis (PMID 31422062))
Clinical implications
- In type 2 diabetes with CKD, semaglutide has trial-grade evidence for slowing progression on a hard kidney composite and is a reasonable addition to guideline-directed therapy (RAS blockade ± SGLT2 inhibitor).
- Do not extrapolate FLOW's hard-endpoint benefit to non-diabetic CKD — no comparable trial exists in that population.
- Interpret albuminuria reduction (LEADER, REWIND, AWARD-7, tirzepatide/SURPASS) as a favourable surrogate signal, not proof of reduced kidney failure; counsel patients accordingly.
- FLOW data suggest the kidney benefit is not abolished by concomitant SGLT2 inhibitor use, supporting combination in appropriate patients.
Limitations
- Several claims — including FLOW's primary kidney results — rest on the paper's abstract rather than full text retrieved this session, so exact effect sizes and confidence intervals are not fully verified here.
- LEADER and REWIND renal composites were not powered for hard endpoints and are dominated by albuminuria transitions; pooling them with FLOW into a single 'kidney protection' effect would misrepresent the evidence.
- All hard-endpoint and most surrogate evidence is confined to type 2 diabetes; there is no comparable randomised hard-endpoint evidence in non-diabetic CKD.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist, and its albuminuria data are pooled post hoc, so it should not be treated as interchangeable class evidence.
- Chart HR values are point estimates drawn from abstracts without uniformly reported confidence intervals and are indicative only.
Open questions
- What are FLOW's exact hazard ratios and confidence intervals for the total kidney composite and for its individual hard components (sustained eGFR loss, kidney failure, renal death)?
- Do GLP-1 receptor agonists slow progression on hard renal endpoints in non-diabetic CKD?
- How much of any hard-endpoint benefit is mediated by albuminuria reduction versus weight, blood pressure, or direct renal mechanisms?
- Is the kidney benefit of GLP-1 RAs fully additive to SGLT2 inhibitors in a prospectively powered combination trial?
- Does tirzepatide (dual agonist) confer hard renal endpoint benefit, or only albuminuria reduction?
References
- [1] 2024 · FLOW trial primary results — semaglutide and kidney outcomes in type 2 diabetes and CKD (abstract-level reference) · PubMed · 38785209 · PubMed · https://pubmed.ncbi.nlm.nih.gov/38785209/
FLOW primary results: significant reduction in the primary kidney composite versus placebo, with benefit extending beyond albuminuria (abstract only; full text not retrieved this session).
- [2] Rossing P, Baeres FMM, Bakris G, et al. · 2023 · The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. · PubMed · 36651820 · Nephrol Dial Transplant · Abstract only · https://pubmed.ncbi.nlm.nih.gov/36651820/
Design/baseline paper describing FLOW as a dedicated kidney-outcomes trial of once-weekly semaglutide in type 2 diabetes and CKD.
- [3] Mann JFE, Ørsted DD, Brown-Frandsen K, et al. (LEADER) · 2017 · Liraglutide and Renal Outcomes in Type 2 Diabetes. · PubMed · 28854085 · N Engl J Med · Abstract only · https://pubmed.ncbi.nlm.nih.gov/28854085/
LEADER renal composite lower with liraglutide; effect driven predominantly by new-onset persistent macroalbuminuria.
- [4] Gerstein HC, Colhoun HM, Dagenais GR, et al. (REWIND) · 2019 · Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. · PubMed · 31189509 · Lancet · Abstract only · https://pubmed.ncbi.nlm.nih.gov/31189509/
REWIND exploratory analysis: reduced renal composite with dulaglutide, largely attributable to new macroalbuminuria.
- [5] Kristensen SL, Rørth R, Jhund PS, et al. · 2019 · Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. · PubMed · 31422062 · Lancet Diabetes Endocrinol · Abstract only · https://pubmed.ncbi.nlm.nih.gov/31422062/
Meta-analysis of CVOTs estimating a favourable pooled kidney composite; composite includes albuminuria components.
- [6] Botros FT, Gerstein HC, Malik R, et al. · 2023 · Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. · PubMed · 37343574 · Diabetes Care · Abstract only · https://pubmed.ncbi.nlm.nih.gov/37343574/
Post hoc REWIND analysis of kidney-function-related outcomes shows a more modest eGFR-based signal.
- [7] Tuttle KR, Rayner B, Lakshmanan MC, et al. · 2021 · Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis. · PubMed · 35373017 · Kidney360 · Abstract only · https://pubmed.ncbi.nlm.nih.gov/35373017/
AWARD-7 exploratory analysis of outcomes by albuminuria status with dulaglutide vs insulin glargine in diabetes and CKD.
- [8] Apperloo EM, Tuttle KR, Pavo I, et al. · 2025 · Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials. · PubMed · 39746157 · Diabetes Care · Abstract only · https://pubmed.ncbi.nlm.nih.gov/39746157/
Pooled post hoc SURPASS-1–5 analysis: tirzepatide reduced albuminuria in type 2 diabetes.
- [9] Neuen BL, Fletcher RA, Heath L, et al. · 2024 · Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. · PubMed · 39210781 · Circulation · Abstract only · https://pubmed.ncbi.nlm.nih.gov/39210781/
Systematic review/meta-analysis of cardiovascular, kidney, and safety outcomes with GLP-1 RAs alone and with SGLT2 inhibitors.
- [10] Mann JFE, Rossing P, Bakris G, et al. · 2024 · Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. · PubMed · 38914124 · Nat Med · Abstract only · https://pubmed.ncbi.nlm.nih.gov/38914124/
FLOW analysis: kidney benefit of semaglutide observed with and without concomitant SGLT2 inhibitor use.
Research information only — not medical advice. Effect sizes are drawn largely from source abstracts (FLOW full text was not verified this session); confirm against the cited primary sources before clinical use.